$579 Million is the total value of Octagon Capital Advisors LP's 35 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 125.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| APLS | Sell | APELLIS PHARMACEUTICALS INC | $170,959,000 | +46.4% | 2,503,059 | -3.1% | 29.50% | -5.4% |
| RCUS | Sell | ARCUS BIOSCIENCES INC | $69,803,000 | +3.2% | 2,668,316 | -0.1% | 12.05% | -33.3% |
| KDNY | CHINOOK THERAPEUTICS INC | $50,166,000 | +12.4% | 2,551,703 | 0.0% | 8.66% | -27.3% | |
| HZNP | Buy | HORIZON THERAPEUTICS PUB L | $38,650,000 | +46.8% | 624,500 | +89.2% | 6.67% | -5.0% |
| GOSS | Sell | GOSSAMER BIO INC | $24,504,000 | +6.1% | 2,045,442 | -25.8% | 4.23% | -31.4% |
| TNDM | New | TANDEM DIABETES CARE INC | $22,725,000 | – | 474,929 | +100.0% | 3.92% | – |
| CLDX | CELLDEX THERAPEUTICS INC NEW | $21,403,000 | +4.3% | 761,398 | 0.0% | 3.69% | -32.6% | |
| XBI | SPDR SER TRs&p biotech | $19,306,000 | +6.8% | 243,400 | 0.0% | 3.33% | -30.9% | |
| MRTX | New | MIRATI THERAPEUTICS INC | $15,435,000 | – | 221,000 | +100.0% | 2.66% | – |
| VRNA | New | VERONA PHARMA PLCsponsored ads | $13,540,000 | – | 1,324,868 | +100.0% | 2.34% | – |
| VERA | Sell | VERA THERAPEUTICS INCcl a | $11,364,000 | +45.2% | 533,264 | -7.3% | 1.96% | -6.1% |
| HRMY | New | HARMONY BIOSCIENCES HLDGS IN | $10,785,000 | – | 243,500 | +100.0% | 1.86% | – |
| ITCI | New | INTRA-CELLULAR THERAPIES INC | $10,281,000 | – | 220,953 | +100.0% | 1.77% | – |
| STOK | STOKE THERAPEUTICS INC | $9,803,000 | -2.8% | 763,456 | 0.0% | 1.69% | -37.1% | |
| BBIO | BRIDGEBIO PHARMA INC | $9,281,000 | +9.5% | 933,743 | 0.0% | 1.60% | -29.2% | |
| ALPN | New | ALPINE IMMUNE SCIENCES INC | $8,820,000 | – | 1,225,000 | +100.0% | 1.52% | – |
| ASND | New | ASCENDIS PHARMA A/Ssponsored adr | $8,622,000 | – | 83,500 | +100.0% | 1.49% | – |
| KRTX | New | KARUNA THERAPEUTICS INC | $7,760,000 | – | 34,500 | +100.0% | 1.34% | – |
| ALNY | New | ALNYLAM PHARMACEUTICALS INC | $7,466,000 | – | 37,300 | +100.0% | 1.29% | – |
| FATE | New | FATE THERAPEUTICS INC | $7,420,000 | – | 331,096 | +100.0% | 1.28% | – |
| New | XILIO THERAPEUTICS INC | $7,057,000 | – | 2,425,000 | +100.0% | 1.22% | – | |
| RNA | Buy | AVIDITY BIOSCIENCES INC | $6,199,000 | +32.7% | 379,629 | +18.0% | 1.07% | -14.2% |
| FDMT | Sell | 4D MOLECULAR THERAPEUTICS IN | $4,020,000 | -9.0% | 499,996 | -21.0% | 0.69% | -41.1% |
| New | NUVALENT INC | $3,888,000 | – | 200,000 | +100.0% | 0.67% | – | |
| JNCE | New | JOUNCE THERAPEUTICS INC | $3,276,000 | – | 1,400,000 | +100.0% | 0.56% | – |
| IMVT | IMMUNOVANT INC | $3,231,000 | +43.1% | 579,061 | 0.0% | 0.56% | -7.5% | |
| DXCM | New | DEXCOM INC | $3,222,000 | – | 40,000 | +100.0% | 0.56% | – |
| AKRO | New | AKERO THERAPEUTICS INC | $2,554,000 | – | 75,000 | +100.0% | 0.44% | – |
| IPSC | Sell | CENTURY THERAPEUTICS INC | $2,218,000 | +1.6% | 224,300 | -13.7% | 0.38% | -34.3% |
| MIRM | New | MIRUM PHARMACEUTICALS INC | $2,101,000 | – | 100,000 | +100.0% | 0.36% | – |
| BGNE | New | BEIGENE LTDsponsored adr | $1,523,000 | – | 11,300 | +100.0% | 0.26% | – |
| MREO | MEREO BIOPHARMA GROUP PLCspon ads | $861,000 | -23.1% | 1,000,000 | 0.0% | 0.15% | -50.2% | |
| CNTB | New | CONNECT BIOPHARMA HLDGS LTDads | $581,000 | – | 450,000 | +100.0% | 0.10% | – |
| BCYC | New | BICYCLE THERAPEUTICS PLCsponsored ads | $465,000 | – | 20,000 | +100.0% | 0.08% | – |
| ADCT | New | ADC THERAPEUTICS SA | $145,000 | – | 30,000 | +100.0% | 0.02% | – |
| AMAM | Exit | AMBRX BIOPHARMA INCsponsored ads | $0 | – | -122,800 | -100.0% | -0.09% | – |
| IMAB | Exit | I MABsponsored ads | $0 | – | -199,876 | -100.0% | -0.60% | – |
| RXDX | Exit | PROMETHEUS BIOSCIENCES INC | $0 | – | -80,000 | -100.0% | -0.60% | – |
| KROS | Exit | KEROS THERAPEUTICS INC | $0 | – | -152,249 | -100.0% | -1.12% | – |
| ARVN | Exit | ARVINAS INC | $0 | – | -178,500 | -100.0% | -2.00% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| APELLIS PHARMACEUTICALS INC | 12 | Q3 2023 | 33.2% |
| ARCUS BIOSCIENCES INC | 12 | Q3 2023 | 18.1% |
| CELLDEX THERAPEUTICS INC NEW | 12 | Q3 2023 | 10.1% |
| GOSSAMER BIO INC | 12 | Q3 2023 | 6.2% |
| 4D MOLECULAR THERAPEUTICS IN | 10 | Q1 2023 | 6.6% |
| BRIDGEBIO PHARMA INC | 10 | Q3 2023 | 6.6% |
| AVIDITY BIOSCIENCES INC | 10 | Q1 2023 | 3.8% |
| VERA THERAPEUTICS INC | 9 | Q2 2023 | 3.5% |
| DYNE THERAPEUTICS INC | 9 | Q3 2023 | 3.5% |
| STOKE THERAPEUTICS INC | 9 | Q2 2023 | 3.7% |
View Octagon Capital Advisors LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-06 |
| SC 13G/A | 2024-02-05 |
| SC 13G | 2024-02-05 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| SC 13G | 2023-01-25 |
| 13F-HR | 2022-11-14 |
View Octagon Capital Advisors LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.